The CEO of U.S.-based pharmaceutical and biotechnology company Moderna said he hopes for a booster shot for its two-dose COVID-19 vaccine to become available in the fall.
“I anticipate in the next year or so, we’re going to see a lot of variants,” Bancel said. “But as more and more people get vaccinated or naturally infected, the pace of the variant is going to slow down and the virus is going to stabilize like you see with flu.”
“I want to make sure there are boost vaccines available in the fall so that we protect people as we go into the next fall and winter season in the U.S.,” he said.
A study published in the New England Journal of Medicine suggests the protection from the Moderna vaccine lasts for at least six months. To this date, Moderna has delivered about 132 million doses of its COVID-19 vaccine globally.
COVID-19 is caused by the CCP virus, commonly referred to as the novel coronavirus, which originated in China in late 2019.
In the research, Bancel noted that teams of scientists will progress clinical data from “variant-specific booster candidates” as soon as possible and will continue to update on its findings.
“We are looking forward to having the clinical data from our variant-specific booster candidates, as well as clinical data from the Phase 2/3 study of our COVID-19 vaccine in adolescents,” Bancel said.
“The new preclinical data on our variant-specific vaccine candidates give us confidence that we can proactively address emerging variants,” he continued. “Moderna will make as many updates to our COVID-19 vaccine as necessary until the pandemic is under control.”
Earlier this year, the company announced it has been developing a new vaccine to use as a third shot, or booster, to combat more contagious variants of the CCP virus, including the variant that was first detected in South Africa.
Bancel also said Wednesday COVID-19 is not going to be “leaving the planet” and reiterated his belief that an annual booster vaccine will become commonplace going forward.
